Behavioural and anatomical characterization of mutant mice with targeted deletion of D1 dopamine receptor-expressing cells: Response to acute morphine

Journal of Pharmacological Sciences

Volumn 121, Issue 1, 2013, Pages 39-47

  Babovic, Daniela ^a   Jiang, Luning ^b   Goto, Satoshi ^c   Gantois, Ilse ^b,e   Schütz, Günter ^d   Lawrence, Andrew J ^b   Waddington, John L ^a   Drago, John ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Basal ganglia; Dopamine; Morphine; Striatum

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; MORPHINE; MU OPIATE RECEPTOR;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ARTICLE; ATTENUATED DIPHTHERIA TOXIN 176 GENE; AUTORADIOGRAPHY; CELL LOSS; CELL MUTANT; CORPUS STRIATUM; DRUG EFFECT; DRUG RESPONSE; ETHOLOGY; EXPLORATORY BEHAVIOR; FEMALE; GENE; GENE DELETION; GENOTYPE; GROOMING; HYPERSENSITIVITY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MASTICATION; MOUSE; MOUSE MUTANT; NEUROANATOMY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REARING; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; STEADY STATE; STRUCTURE ANALYSIS; WILD TYPE;

EID: 84873840354     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12214FP     Document Type: Article

References (47)

1. Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol. 2002;66:285-306.
2. Mori T, Ito S, Narita M, Suzuki T, Sawaguchi T. Combined effects of psychostimulants and morphine on locomotor activity in mice. J Pharmacol Sci. 2004;96:450-458.
3. David V, Polis I, McDonald J, Gold LH. Intravenous self-admin istration of heroin/cocaine combinations (speedball) using nosepoke or lever-press operant responding in mice. Behav Pharmacol. 2001;12:25-34.
4. Masukawa Y, Suzuki T, Misawa M. Differential modification of the rewarding effects of methamphetamine and cocaine by opioids and antihistamines. Psychopharmacology (Berl). 1993;111: 139-143.
5. Hemby SE, Co C, Dworkin SI, Smith JE. Synergistic elevations in nucleus accumbens extracellular dopamine concentrations during self-administration of cocaine/heroin combinations (Speedball) in rats. J Pharmacol Exp Ther. 1999;288:274-280.
6. Zernig G, O'Laughlin IA, Fibiger HC. Nicotine and heroin augment cocaine-induced dopamine overflow in nucleus accumbens. Eur J Pharmacol. 1997;337:1-10.
7. Stevens KE, Mickley GA, McDermott LJ. Brain areas involved in production of morphine-induced locomotor hyperactivity of the C57B1/6J mouse. Pharmacol Biochem Behav. 1986;24: 1739-1747.
8. Patti CL, Frussa-Filho R, Silva RH, Carvalho RC, Kameda SR, Takatsu-Coleman AL, et al. Behavioral characterization of morphine effects on motor activity in mice. Pharmacol Biochem Behav. 2005;81:923-927.
9. Brown RM, Short JL, Cowen MS, Ledent C, Lawrence AJ. A differential role for the adenosine A2A receptor in opiate reinforcement vs opiate-seeking behavior. Neuropsychopharmacology. 2009;34:844-856.
10. Belknap JK, Riggan J, Cross S, Young ER, Gallaher EJ, Crabbe JC. Genetic determinants of morphine activity and thermal responses in 15 inbred mouse strains. Pharmacol Biochem Behav. 1998;59:353-360.
11. Kuribara H, Tadokoro S. Reverse tolerance to ambulation-increasing effects of methamphetamine and morphine in 6 mouse strains. Jpn J Pharmacol. 1989;49:197-203.
12. Iwamoto ET. Locomotor activity and antinociception after putative mu, kappa and sigma opioid receptor agonists in the rat: influence of dopaminergic agonists and antagonists. J Pharmacol Exp Ther. 1981;217:451-460.
13. Serrano A, Aguilar MA, Manzanedo C, Rodriguez-Arias M, Minarro J. Effects of DA D1 and D2 antagonists on the sensitisation to the motor effects of morphine in mice. Prog Neuropsy-chopharmacol Biol Psychiatry. 2002;26:1263-1271.
14. Brown RM, Lawrence AJ. Neurochemistry underlying relapse to opiate seeking behaviour. Neurochem Res. 2009;34:1876-1887.
15. Bossert JM, Ghitza UE, Lu L, Epstein DH, Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur J Pharmacol. 2005;526:36-50.
16. Shaham Y, Stewart J. Effects of opioid and dopamine receptor antagonists on relapse induced by stress and re-exposure to heroin in rats. Psychopharmacology (Berl). 1996;125:385-391.
17. Hosohata Y, Vanderah TW, Burkey TH, Ossipov MH, Kovelowski CJ, Sora I, et al. delta-Opioid receptor agonists produce antinociception and [35S]GTPgammaS binding in mu receptor knockout mice. Eur J Pharmacol. 2000;388:241-248.
18. Qiu C, Sora I, Ren K, Uhl G, Dubner R. Enhanced delta-opioid receptor-mediated antinociception in mu-opioid receptor-deficient mice. Eur J Pharmacol. 2000;387:163-169.
19. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioidreceptor gene. Nature. 1996;383:819-823.
20. Sora I, Elmer G, Funada M, Pieper J, Li XF, Hall FS, et al. Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve. Neuropsychopharmacology. 2001;25:41-54.
21. Gantois I, Fang K, Jiang L, Babovic D, Lawrence AJ, Ferreri V, et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. Proc Natl Acad Sci U S A. 2007;104:4182-4187.
22. Babovic D, Jiang L, Gantois I, Lawrence AJ, Ferreri V, Schutz G, et al. Age-related behavioural phenotype and cellular characterisation of mice with progressive ablation of D1 dopamine receptor-expressing cells. Behavioural Brain Res. 2010;206:78-87.
23. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 1990;13:244-254.
24. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci. 1992;15:285-320.
25. Sato K, Sumi-Ichinose C, Kaji R, Ikemoto K, Nomura T, Nagatsu I, et al. Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc Natl Acad Sci U S A. 2008;105:12551-12556.
26. Canales JJ, Graybiel AM. A measure of striatal function predicts motor stereotypy. Nat Neurosci. 2000;3:377-383.
27. Zhang Q, Li JX, Zheng JW, Liu RK, Liang JH. L-type Ca(2+) channel blockers inhibit the development but not the expression of sensitization to morphine in mice. Eur J Pharmacol. 2003; 467:145-150.
28. Babovic D, O'Tuathaigh CM, O'Sullivan GJ, Clifford JJ, Tighe O, Croke DT, et al. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav Brain Res. 2007;183:236-239.
29. O'Tuathaigh CM, O'Sullivan GJ, Kinsella A, Harvey RP, Tighe O, Croke DT, et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport. 2006;17:79-83.
30. Waddington JL, O'Tuathaigh C, O'Sullivan G, Tomiyama K, Koshikawa N, Croke DT. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology. 2005;181: 611-638.
31. Narita M, Suzuki T, Misawa M, Nagase H. Antagonism of the morphine-induced Straub tail reaction by kappa-opioid receptor activation in mice. Psychopharmacology (Berl). 1993;110: 254-256.
32. Zarrindast MR, Alaei-Nia K, Shafizadeh M. On the mechanism of tolerance to morphine-induced Straub tail reaction in mice. Pharmacol Biochem Behav. 2001;69:419-424.
33. Teper Y, Whyte D, Cahir E, Lester HA, Grady SR, Marks MJ, et al. Nicotine-induced dystonic arousal complex in a mouse line harboring a human autosomal-dominant nocturnal frontal lobe epilepsy mutation. J Neurosci. 2007;27:10128-10142.
34. Djouma E, Lawrence AJ. The effect of chronic ethanol consumption and withdrawal on mu-opioid and dopamine D(1) and D(2) receptor density in Fawn-Hooded rat brain. J Pharmacol Exp Ther. 2002;302:551-559.
35. Lawrence AJ, Krstew E, Jarrott B. Functional dopamine D2 receptors on rat vagal afferent neurones. Br J Pharmacol. 1995; 114:1329-1334.
36. Sako W, Morigaki R, Nagahiro S, Kaji R, Goto S. Olfactory type G-protein alpha subunit in striosome-matrix dopamine systems in adult mice. Neuroscience. 2010;170:497-502.
37. Sako W, Morigaki R, Kaji R, Tooyama I, Okita S, Kitazato K, et al. Identification and localization of a neuron-specific isoform of TAF1 in rat brain: implications for neuropathology of DYT3 dystonia. Neuroscience. 2011;189:100-107.
38. Longoni R, Spina L, Di Chiara G. Dopaminergic D-1 receptors: essential role in morphine-induced hypermotility. Psychopharmacology (Berl). 1987;93:401-402.
39. Dogrul A, Yesilyurt O. Effects of Ca2+ channel blockers on apomorphine, bromocriptine and morphine-induced locomotor activity in mice. Eur J Pharmacol. 1999;364:175-182.
40. Manzanedo C, Aguilar MA, Minarro J. The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice. Psychopharmacology (Berl). 1999;143:82-88.
41. Rodriguez-Arias M, Broseta I, Aguilar MA, Minarro J. Lack of specific effects of selective D(1) and D(2) dopamine antagonists vs. risperidone on morphine-induced hyperactivity. Pharmacol Biochem Behav. 2000;66:189-197.
42. Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J, Waddington JL. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology. 1998;37:1595-1602.
43. Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Rep. 2004;5:30-34.
44. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med. 1988;318:876-880.
45. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990;28:547-555.
46. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse. 1991;9:43-49.
47. Moratalla R, Quinn B, DeLanney LE, Irwin I, Langston JW, Graybiel AM. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci U S A. 1992;89:3859-3863.